What's Happening?
Dihydroberberine (DHB) is gaining attention in the dietary supplement market for its improved bioavailability compared to standard berberine. Both compounds share the same core pharmacology, but DHB's structural modification makes it more lipophilic,
enhancing its absorption across the gut wall. This has led to higher systemic berberine levels in preclinical studies. Despite its pharmacokinetic advantages, DHB is not FDA-approved and is marketed under the Dietary Supplement Health and Education Act (DSHEA). The supplement is primarily used for its potential metabolic benefits, including improved glycemic control and insulin sensitivity.
Why It's Important?
The introduction of DHB as a supplement highlights the ongoing innovation in the nutraceutical industry, particularly in enhancing the bioavailability of compounds with known health benefits. This development could influence consumer choices, especially among those seeking natural alternatives for metabolic health management. However, the lack of FDA approval and limited clinical trials on DHB compared to standard berberine raises questions about its efficacy and safety. This underscores the need for further research and regulatory scrutiny to ensure consumer safety and product efficacy.
